Charles Sternberg, Associate Editor07.06.22
Getinge has completed the previously announced acquisition of 100% of the shares in Fluoptics SAS, a French leader in fluorescence imaging as an aid to surgery.
All conditions for the transaction and closing have now been fulfilled. Getinge has paid approximately €23 million ($23.4 million) in cash on closing for 100% of the shares on a cash and debt free basis, which is subject to further post-closing adjustments. Moreover, additional earn-out may be paid if agreed milestones are achieved.
The acquisition was financed through available cash. Getinge expects no material integration costs.
The acquisition will expand Getinge’s customer offering in clinical decision support by providing safe and improved operating efficiency. The addressable global market is estimated to be more than SEK 2.5 billion, recording an annual compounded average growth rate of 8% during the forecasted period (2020-2025). More than 380 institutions in the U.S., Europe and Asia are currently using the Fluoptics technology in their daily clinical routine with over 40,000 procedures performed.
All conditions for the transaction and closing have now been fulfilled. Getinge has paid approximately €23 million ($23.4 million) in cash on closing for 100% of the shares on a cash and debt free basis, which is subject to further post-closing adjustments. Moreover, additional earn-out may be paid if agreed milestones are achieved.
The acquisition was financed through available cash. Getinge expects no material integration costs.
The acquisition will expand Getinge’s customer offering in clinical decision support by providing safe and improved operating efficiency. The addressable global market is estimated to be more than SEK 2.5 billion, recording an annual compounded average growth rate of 8% during the forecasted period (2020-2025). More than 380 institutions in the U.S., Europe and Asia are currently using the Fluoptics technology in their daily clinical routine with over 40,000 procedures performed.